ADX-629 Therapy for Sjogren-Larsson Syndrome
NCT05443685
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
8
Enrollment
OTHER
Sponsor class
Conditions
Sjogren-Larsson Syndrome
Interventions
DRUG:
ADX-629
Sponsor
University of Nebraska